Sputnik V vaccination results in production o protective neutralizing antibody titers against new strains, including British, South African, Brazilian, Indian variants and variants B.1.1.141 and B. 1. 1. 317 identified in Moscow with mutations in the receptor-binding domain (RBD), the Gamaleya Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) report. The confirming data were obtained based on the analysis of the neutralizing activity of blood serum taken from vaccinated patients.
“The research methodology is based on the assessment of virus-neutralizing activity (VNA) with the use of a live virus, which allows us to obtain the most reliable data and corresponds to the gold standard. The study compared the VNA of human blood serum after vaccination with Sputnik V on samples of internationally represented strains with VNA against the original strain B.1.1.1. Blood serum was collected from individuals immunized with both components of Sputnik V,” the report says.
The research methodology of the Gamaleya Research Institute of Epidemiology and Microbiology is described in an article published in the international journal Vaccines on July 12, 2021. VNA testing has no direct connection with the effectiveness of the vaccine.
It is noted that the obtained data demonstrate that Sputnik V also have protective properties against new strains. Sputnik V was found to have significantly lower decrease in the level of viral neutralizing activity for a number of strains compared to the data published by manufacturers of other vaccines, which previously confirmed the effectiveness of their products against new mutations of coronavirus.
the Gamaleya Research Institute of Epidemiology and Microbiology is actively studying new strains of SARS-CoV-2 to assess the VNA and the efficacy of Sputnik V vaccine as the variants arise in different regions of the world. The Center and RDIF are also considering the possibility of creating mix-and-match sets of vaccines together with other leading manufacturers based on the first shot of Sputnik V.
“Our studies demonstrate good results for Sputnik V vaccine in terms of its efficacy against new strains of SARS-CoV-2. We are getting more and more data from around the world about the ability of the coronavirus to transform and mutate. Today, Sputnik V is one of the most effective vaccines against both the original and new strains of coronavirus due to the unique approach based on the use of two different adenoviral vectors as delivery tools,” said Alexander Ginzburg, director of the Gamaleya Research and Development Center.
Sputnik V was the first vaccine to use two different adenoviral vectors at the same time. Studies of the Gamalei Center have demonstrated the appropriateness of this approach as the virus neutralizing activity of the vaccine against new, more dangerous strains was higher than that of many other vaccines. RDIF will continue to support further research on the effectiveness of Sputnik V against new strains and is analyzing the possibilities of partnership with other leading manufacturers to create mix-and-match of vaccines based on the first shot of Sputnik V,” said Kirill Dmitriev, CEO of RDIF.
To date, Sputnik V has been registered in 67 countries with a total population of more than 3.5 billion people. According to data from regulators from a number of countries, including Mexico, Argentina, Serbia, Bahrain, Hungary, San Marino, the United Arab Emirates, and other states, obtained during vaccination of the population, demonstrate that Sputnik V is one of the safest and most successful vaccines against coronavirus.
